Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Differential regulation of Lipocalin 2 (LCN2) in doxorubicin-resistant 4T1 triple negative breast cancer cells — Steffen K. Meurer (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Differential regulation of Lipocalin 2 (LCN2) in doxorubicin-resistant 4T1 triple negative breast cancer cells
RW
Shared by
Ralf Weiskirchen
Differential regulation of Lipocalin 2 (LCN2) in doxorubicin-resistant 4T1 triple negative breast cancer cells
Article
2020
en
Authors
+1 more
SM
Steffen K. Meurer
OT
Okan Tezcan
TL
Twan Lammers
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2025
Lipocalin-2 in Triple-Negative Breast Cancer: A Review of Its Pathophysiological Role in the Metastatic Cascade
Diandra T. Keller
,
Ralf Weiskirchen
,
Sarah K. Schröder
Article
2016
Selection of Novel Peptides Homing the 4T1 CELL Line: Exploring Alternative Targets for Triple Negative Breast Cancer
Article
2015
Lipocalin 2 (LCN2) in hepatic inflammation
Anastasia Asimakopoulou
,
Erawan Borkham‐Kamphorst
,
Ralf Weiskirchen
Article
2010
Lipocalin 2 (LCN2) in experimental liver injury
Erawan Borkham‐Kamphorst
,
F Drews
,
Ralf Weiskirchen
Article
2020
Triple negative breast cancer in the era of miRNA
Hussein Sabit
,
Emre Çevik
,
Hüseyin Tombuloğlu
,
Shaimaa Abdel-Ghany
,
Güzin Tombuloğlu
,
Manel Esteller
Discussion(0)
No comments yet. Be the first to comment.